VIA
PTCT icon

Virtus Investment Advisers’s PTC Therapeutics PTCT Stock Holding History

Virtus Investment Advisers’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Buy
15,476
+4,316
+39% +$312K 0.29% 167
2026
Q1 		$760K Buy
11,160
+2,127
+24% +$151K 0.21% 167
2025
Q4 		$686K Buy
9,033
+316
+4% +$23K 0.19% 176
2025
Q3 		$535K Hold
8,717
– – 0.15% 198
2025
Q2 		$426K Buy
8,717
+1,134
+15% +$53.8K 0.14% 216
2025
Q1 		$386K Buy
+7,583
New +$378K 0.11% 212

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Virtus Investment Advisers's PTCT Position: Q2 2026 in Review

Virtus Investment Advisers increased its PTC Therapeutics (PTCT) stake by 39% in Q2 2026, buying an estimated $312K and bringing the position to 15,476 shares worth $1.26M. The position accounts for 0.29% of the portfolio, ranked #167.

Virtus Investment Advisers first reported a position in PTCT in Q1 2025 and has held it in 6 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Virtus Investment Advisers held 15,476 shares of PTC Therapeutics worth $1.26M as of Q2 2026.
  • Virtus Investment Advisers bought 4,316 PTC Therapeutics shares in Q2 2026, an estimated $312K.
  • PTC Therapeutics made up 0.29% of Virtus Investment Advisers's portfolio in Q2 2026, its #167 holding.
  • Virtus Investment Advisers first reported a position in PTC Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.